XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53Manman Deng, Ken H. Young, Mingzhi Zhang et al.|Journal of Hematology & Oncology|2020Cited by 56
Aggressive B-cell Lymphoma with MYC/TP53 Dual Alterations Displays Distinct Clinicopathobiological Features and Response to Novel Targeted AgentsManman Deng, Ken H. Young, Zijun Y. Xu‐Monette et al.|Molecular Cancer Research|2020Cited by 38
A composite single-nucleotide polymorphism prediction signature for extranodal natural killer/T-cell lymphomaXiao‐Peng Tian, Qingqing Cai, Shu‐Yun Ma et al.|Blood|2021Cited by 30
Molecular and genetic biomarkers implemented from next-generation sequencing provide treatment insights in clinical practice for Waldenström macroglobulinemiaYingjun Wang, Ken H. Young, Vasantha Lakshmi Gali et al.|Neoplasia|2021Cited by 29
Clinical outcomes and microenvironment profiling in relapsed/refractory multiple myeloma patients with extramedullary disease receiving anti‐<scp>BCMA CAR</scp> T‐cell‐based therapyYuekun Qi, Jiang Cao, Gang Wang et al.|American Journal of Hematology|2024Cited by 21